Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 04, 2026
Why Is UL Solutions (ULS) Stock Down -14.71% Today?

Why Is UL Solutions (ULS) Stock Down -14.71% Today?

Key Takeaways

  • UL Solutions shares plunged 14.71% to $77.66 as of midday trading Tuesday, following the release of second-quarter 2026 financial results.
  • The sell-off came despite an earnings beat — adjusted EPS of $0.59 topped the $0.51 consensus — signaling investor disappointment with forward-looking details.
  • Free cash flow margin contracted to 11.2% from 13.5% a year ago, while capex guidance was raised sharply to ~8.5% of revenue, the highest level in recent years.
  • Analyst projections pointed to a growth deceleration, with forward revenue estimates of just 4.9%, below the company's recent trajectory.
  • The decline was entirely company-specific, as the broader market rallied to record highs on easing Middle East tensions and strong earnings from industrial peers.
  • Traders are now watching whether management can deliver on margin targets amid rising compensation and acquisition-integration costs in the second half of 2026.

Opening Summary

ULS, the stock of UL Solutions Inc. — the Illinois-based testing, inspection, and certification giant founded in 1894 — suffered a dramatic intraday rout on Tuesday, tumbling 14.71% to $77.66. The prior session's close stood at $91.05 on August 3, 2026. The plunge erased billions in market value and came despite second-quarter results that beat profit expectations, as investors zeroed in on contracting free cash flow, elevated capital spending plans, and a projected slowdown in revenue growth.

Earnings Beat Overshadowed by Cash Flow and Spending Concerns

UL Solutions delivered what, on the surface, looked like a solid second quarter. Revenue rose 5.2% year-over-year to $816 million, roughly in line with Wall Street's $814.3 million estimate. Adjusted earnings per share hit $0.59, beating the $0.51 consensus by 15.7%. Adjusted EBITDA reached a quarterly record of $219 million, with margins expanding 140 basis points to 26.8% — the highest in company history. Organic revenue growth clocked in at 6.6%, led by the Industrial and Consumer segments.

Yet the market's reaction was ruthless. The primary culprit was free cash flow. The company's free cash flow margin fell to 11.2%, down from 13.5% in the same quarter a year earlier, signaling that UL Solutions was becoming less efficient at converting profits into actual cash. For a stock that entered the report trading at a lofty price-to-earnings multiple above 50 and with a 27% six-month rally, that deterioration in cash generation was enough to trigger a sharp re-rating.

Elevated Capex and Margin Pressure in the Outlook

Management reaffirmed its full-year 2026 guidance for mid-single-digit organic revenue growth and an adjusted EBITDA margin of approximately 27.0%. However, the company also raised its capital expenditure forecast to roughly 8.5% of revenue — a meaningful step up from the 6.5% level recorded in 2025 and above the long-term target range of 6% to 8%. The elevated spending reflects investments in laboratory capacity, modernization, and new testing capabilities tied to AI data centers, energy storage, and automotive electrification.

During the earnings call, analysts pressed management on whether second-half margins could hold given rising performance-based compensation expenses and integration costs associated with the planned acquisition of the Eurofins Electrical & Electronics testing business. While management expressed confidence in meeting full-year targets, the combination of higher capex, compensation headwinds, and M&A integration costs appeared to outweigh the second-quarter beat in the eyes of investors.

Growth Deceleration and Valuation Reassessment

Adding to the bearish case, forward-looking analyst estimates project revenue growth of just 4.9% over the next twelve months — a notable deceleration from the 6.8% annualized pace delivered over the prior two years. For a company that had commanded a premium valuation partly on the strength of its growth narrative, even a modest projected slowdown was enough to spark a repositioning.

The company continues to reshape its portfolio, exiting lower-margin service lines and completing the sale of its Employee Health and Safety software business. While these moves improve the quality of earnings over the long run, they also create near-term revenue headwinds, with roughly 1% of revenue expected to be lost from restructuring-related business exits in 2026. The restructuring plan is nearly complete, with only about $3 million in remaining pre-tax charges expected through early 2027, but the transition period has left investors questioning the pace of organic expansion.

Market Context and Trading Activity

The plunge in ULS shares stood in stark contrast to the broader market on Tuesday. The Dow Jones Industrial Average surged more than 780 points, while the S&P 500 opened in record territory, buoyed by easing U.S.-Iran tensions, a pullback in crude oil prices, and strong earnings from industrial heavyweights like CAT. This divergence underscores that the sell-off in UL Solutions was entirely company-driven rather than a reflection of sector or macro weakness.

Trading volume was elevated well above the daily average, reflecting intense investor repositioning following the earnings release. The stock sliced through multiple technical support levels, including its 50-day moving average, and traded at levels not seen since mid-July. With the 52-week range spanning $61.64 to $107.54, the shares are now firmly in the lower half of that band.

What Comes Next for ULS

The coming weeks will test whether UL Solutions can restore investor confidence. Management has maintained its full-year margin target of approximately 27.0%, and the secular tailwinds the company cites — energy transition, electrification, automation, and AI infrastructure — remain intact as long-term demand drivers for safety, certification, and compliance services. The Eurofins acquisition, once integrated, could strengthen the company's competitive position in electrical and electronics testing.

However, risks remain. If macroeconomic uncertainty causes customers to delay or cancel testing and certification projects, revenue growth could fall short of already-modest expectations. The elevated capex cycle, while strategically justified, will need to show tangible returns before the market is willing to re-rate the stock higher. The next major catalyst will be third-quarter results, where investors will scrutinize free cash flow recovery and margin resilience against the backdrop of rising costs.

Trending AI Robots

For traders seeking data-driven strategies in volatile markets like the one affecting ULS today, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this dynamically updated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore a range of approaches suited to different market environments. Visit the Trending AI Robots page to discover which strategies are delivering results right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ULS

ULS in downward trend: price dove below 50-day moving average on July 06, 2026

ULS moved below its 50-day moving average on July 06, 2026 date and that indicates a change from an upward trend to a downward trend. In of 19 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 30 cases where ULS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ULS as a result. In of 35 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ULS turned negative on August 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ULS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ULS entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ULS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ULS advanced for three days, in of 147 cases, the price rose further within the following month. The odds of a continued upward trend are .

ULS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ULS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.747) is normal, around the industry mean (7.685). P/E Ratio (31.589) is within average values for comparable stocks, (74.493). Projected Growth (PEG Ratio) (1.783) is also within normal values, averaging (1.532). Dividend Yield (0.007) settles around the average of (0.020) among similar stocks. P/S Ratio (5.068) is also within normal values, averaging (8.897).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ULS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Industry description

The industry produces equipment regularly used in offices by businesses and other organizations, and could range from items like Blank sheet paper, calendars, Label and adhesive paper, paper clips, janitorial supplies, to larger /higher cost products like computers, printers, photocopiers, office furniture and so on. Many businesses in the office supply industry have been expanding into related markets like business cards, plus printing and binding of high quality, high volume business and engineering documents. Some companies in this industry also offer shipping services, including packaging and bulk mailing. Herman Miller, Inc., Steelcase Inc. and HNI Corporation.

Market Cap

The average market capitalization across the Office Equipment/Supplies Industry is 7.9B. The market cap for tickers in the group ranges from 359.74K to 89.97B. MCHSF holds the highest valuation in this group at 89.97B. The lowest valued company is JFIL at 359.74K.

High and low price notable news

The average weekly price growth across all stocks in the Office Equipment/Supplies Industry was 3%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 4%. THH experienced the highest price growth at 27%, while ULS experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Office Equipment/Supplies Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 52
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 84
Seasonality Score: -34 (-100 ... +100)
View a ticker or compare two or three
ULS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry OfficeEquipmentSupplies

Profile
Details
Industry
N/A
Address
333 Pfingsten Road
Phone
+1 847 272–8800
Employees
15233
Web
https://www.ul.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.